6.29

4.49% 0.27

Pre-market: 6.41 0.12 +1.91%

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $6.29, with a volume of 2.24M. It is up +4.49% in the last 24 hours and up +48.35% over the past month. Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Previous Close:

$6.02

Open:

$6.02

24h Volume:

2.24M

Relative Volume:

0.50

Market Cap:

$601.64M

Revenue:

$829.00M

Net Income/Loss:

$-399.90M

P/E Ratio:

-1.4574

EPS:

-4.3159

Net Cash Flow:

$-23.20M

1W Performance:

+12.93%

1M Performance:

+48.35%

6M Performance:

+29.96%

1Y Performance:

-22.63%

1-Day Range:

$0.00

1-Week Range:

$5.39

$6.34

52-Week Range:

$2.74

$8.50

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1053)

Industry

Diagnostics & Research (44)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2026-11-04

Latest SEC Filings

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, NTRA, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYGN Myriad Genetics Inc	6.29	601.64M	829.00M	-399.90M	-23.20M	-4.3159
TMO Thermo Fisher Scientific Inc	693.02	256.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.00	163.09B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	410.82	59.22B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	177.49	50.04B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	468.55	46.03B	3.77B	449.25M	240.68M	7.8556

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-26	Upgrade	Piper Sandler	Underweight → Neutral
Sep-09-26	Resumed	UBS	Neutral
Sep-01-26	Downgrade	Piper Sandler	Overweight → Underweight
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight
Feb-12-25	Initiated	Craig Hallum	Buy
Dec-10-24	Initiated	UBS	Neutral
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Underperform
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

Oct 26, 2026

Labcorp to spend $932 million on lab assets, acquire Millennium Health - Winston-Salem Journal

Oct 26, 2026

Oct 22, 2026

Labcorp to buy Myriad’s prenatal health testing unit for $210M - MedTech Dive

Oct 22, 2026

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers - The Manila Times

Oct 22, 2026

Myriad Genetics presents data on cancer recurrence detection test By Investing.com - Investing.com Canada

Oct 22, 2026

Myriad Genetics releases MRD cancer detection data at ESMO 2026 - StreetInsider

Oct 22, 2026

Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions - Yahoo Finance

Oct 22, 2026

After surgery, a test detected cancer DNA before each observed colorectal recurrence; median lead: 4 months. - Stock Titan

Oct 22, 2026

Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) - Seeking Alpha

Oct 22, 2026

Oct 21, 2026

Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner - Yahoo Finance

Oct 21, 2026

Myriad Genetics to present at Wells Fargo healthcare conference - scanx.trade

Oct 21, 2026